102.13

2.14% 2.14

After Hours: 102.89 0.76 +0.74%

Spyre Therapeutics Inc (SYRE)

Overview News Price History Financials Discussions Forecast

Spyre Therapeutics Inc stock is traded at $102.13, with a volume of 809.67K. It is up +2.14% in the last 24 hours and up +18.43% over the past month. Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Previous Close:

$99.99

Open:

$100.56

24h Volume:

809.67K

Relative Volume:

0.63

Market Cap:

$8.87B

Revenue:

$688.00K

Net Income/Loss:

$-168.74M

P/E Ratio:

-43.32

EPS:

-2.3577

Net Cash Flow:

$-185.87M

1W Performance:

+1.90%

1M Performance:

+18.43%

6M Performance:

+218.81%

1Y Performance:

+480.28%

1-Day Range:

$98.79

$103.57

1-Week Range:

$97.00

$103.57

52-Week Range:

$14.51

$105.09

Spyre Therapeutics Inc Stock (SYRE) Company Profile

Name

Spyre Therapeutics Inc

Sector

Healthcare (1071)

Industry

Biotechnology (598)

Phone

(617) 651-5940

Address

221 CRESCENT STREET, WALTHAM

Employee

112

Twitter

Next Earnings Date

2026-08-04

Latest SEC Filings

SYRE's Discussions on Twitter

Compare SYRE vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SYRE Spyre Therapeutics Inc	102.13	8.68B	688.00K	-168.74M	-185.87M	-2.3577
VRTX Vertex Pharmaceuticals Inc	477.36	120.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	656.01	68.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	918.22	57.84B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	189.23	40.13B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	271.77	35.88B	4.29B	577.22M	641.34M	4.2086

Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-14-26	Initiated	Raymond James	Strong Buy
Dec-18-25	Initiated	Mizuho	Outperform
Dec-17-25	Initiated	Citigroup	Buy
Sep-26-25	Initiated	Deutsche Bank	Buy
Apr-08-25	Initiated	Leerink Partners	Outperform
Mar-18-25	Initiated	Wolfe Research	Outperform
Sep-04-24	Initiated	Wedbush	Outperform
Jul-16-24	Initiated	Evercore ISI	Outperform
May-02-24	Initiated	Robert W. Baird	Outperform
Mar-01-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Dec-20-23	Initiated	BTIG Research	Buy
Dec-11-23	Initiated	Guggenheim	Buy
Dec-11-23	Initiated	Jefferies	Buy
May-04-20	Initiated	Piper Sandler	Overweight
Mar-21-19	Initiated	JP Morgan	Overweight
Sep-04-18	Downgrade	Wells Fargo	Outperform → Market Perform
Apr-24-18	Initiated	Evercore ISI	Outperform
Mar-14-18	Reiterated	Needham	Buy

View All

Spyre Therapeutics Inc Stock (SYRE) Latest News

Jul 23, 2026

ETFs Investing in Spyre Therapeutics, Inc Stocks - TradingView

Jul 23, 2026

Jul 21, 2026

Spyre Therapeutics, Inc. earns Great Place to Work certification for 2026 - Traders Union

Jul 21, 2026

Jul 17, 2026

SYRE Stock Draws Analyst Upgrades As Volatility Spikes - StocksToTrade

Jul 17, 2026

Jul 14, 2026

Why Spyre Therapeutics (SYRE) Stock Is Up Today - Quiver Quantitative

Jul 14, 2026

Spyre Therapeutics stock hits 52-week high at 102.46 USD By Investing.com - Investing.com Nigeria

Jul 14, 2026

Spyre Therapeutics stock hits 52-week high at 102.46 USD - Investing.com

Jul 14, 2026

Jul 13, 2026

Spyre Therapeutics (SYRE) Slides 4.1% as Biotech Sector Faces HeadwindsIchimoku Cloud - dars.gov.et

Jul 13, 2026

Mizuho raises Spyre stock price target to $120 on IBD data - Investing.com UK

Jul 13, 2026

Spyre Therapeutics, Inc. participates in key Boston investor event - Traders Union

Jul 13, 2026

Mizuho raises Spyre stock price target to $120 on IBD data By Investing.com - Investing.com South Africa

Jul 13, 2026

SYRE Maintained by Mizuho -- Price Target Raised to $120 - GuruFocus

Jul 13, 2026

Mizuho Raises Price Target on Spyre Therapeutics to $120 From $84, Keeps Outperform Rating - marketscreener.com

Jul 13, 2026

Jul 11, 2026

SYRE Stock Marks Best Session In About 3 Years — Here’s Why - Stocktwits

Jul 11, 2026

LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $119 - Moomoo

Jul 11, 2026

Spyre Therapeutics Insider Sold Shares Worth $1,315,346, According to a Recent SEC Filing - Moomoo

Jul 11, 2026

Jul 10, 2026

Spyre Therapeutics (SYRE) Faces Broad Russell Index Removal Is Benchmark Appeal Quietly Eroding? - simplywall.st

Jul 10, 2026

Jul 09, 2026

LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $119 - Moomoo

Jul 09, 2026

Jul 08, 2026